ReproCell Stock

ReproCell Net Debt/Equity

The Net Debt to Equity Ratio of ReproCell (4978.T) as of Sep 14, 2026 is -0.44. In the previous year, Net Debt to Equity Ratio was -0.79 — a change of -44.48% (higher).

Net Debt/Equity

-0.44

YoY

-44.48%

Last updated:

Net Debt to Equity Ratio of ReproCell is 2026 -0.44 . Net Debt to Equity Ratio of ReproCell was 2025 -0.79 . It decreases by -44.48% higher compared to the previous year.

The ReproCell Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2018
-0.88 JPY
Jan 1, 2019
-0.80 JPY
Jan 1, 2020
-0.84 JPY
Jan 1, 2021
-0.84 JPY
Jan 1, 2022
-0.63 JPY
Jan 1, 2023
-0.84 JPY
Jan 1, 2024
-0.79 JPY
Jan 1, 2025
-0.44 JPY
The ReproCell Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.44-44.48%
-0.79-6.18%
-0.84+33.85%
-0.63-25.07%
-0.84-0.49%
-0.84+5.91%
-0.80-9.34%
-0.88+21.55%
-0.72-1.18%
-0.73+7.16%
-0.68-30.32%
-0.98
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Net Debt to Equity Ratio of ReproCell is -0.44 in 2026.

Net Debt to Equity Ratio of ReproCell changed from -0.79 to -0.44, representing a -44.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio ReproCell since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's ReproCell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — ReproCell

All Key Metrics — ReproCell